Journal club: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

Summary: <p>Only one treatment is licensed for idiopathic pulmonary fibrosis and this only in Europe. Luca Richeldi (Center for Rare Lung Diseases, University of Modena, Italy) describes his phase 2 trial of a tyrosine kinase inhibitor to see if it could be safely and effectively used in patients with the disease. Dr Richeldi’s research was published in the New England Journal of Medicine.</p><p>See also:</p><p>http://www.nejm.org/doi/full/10.1056/NEJMoa1103690</p>